# Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

> **NCT06662877** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 206 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Second Line Treatment
- Chemotherapy
- Tyrosine Kinase Inhibitor

## Interventions

- **DRUG:** Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib
- **DRUG:** Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)

## Key facts

- **NCT ID:** NCT06662877
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2029-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2024-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662877, "Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06662877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*